Rapafusyn Pharmaceuticals Raises $28M in Funding to Advance Drug Development

Rapafusyn Pharmaceuticals Raises $28M in Series A Funding

(Linkedin), a research services company based in the United States, recently secured $28M in Series A funding to advance their innovative approach to drug discovery and development. They specialize in utilizing macrocyclic peptide-based non-degrading molecular glues (RapaGlues™) to target challenging therapeutic areas.

Funding Amount: $28 million

Industry: Research Services

Employee Count: 11-50

What Rapafusyn Pharmaceuticals needs to buy: Rapafusyn Pharmaceuticals is seeking partnerships with pharmaceutical companies, biotech and research institutions, and investors in biotechnology. They are looking for collaborations in drug discovery and development using non-degrading molecular glues, as well as manufacturing and supply chain solutions, and regulatory and compliance services to support their innovative therapeutic drug development efforts.

Rapafusyn Pharmaceuticals Raises $28M in Funding to Advance Drug Development

Read more

Supio Raises $25M in Series A Funding for AI Platform and Operational Expansion

Katara Raises $2.2M in Funding for Expansion

"Planera Raises $13.5M in Funding to Expand Construction Scheduling Platform"

pgEdge Raises $10M for Expansion and Innovation in Distributed PostgreSQL Market